RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

Data ReadoutpositiveRXR Nuclear Receptor AgonistPositive

AI Analysis

Summary

Io Therapeutics announces preclinical research showing its RXR Nuclear Receptor Agonist candidate degrades and reduces alpha-synuclein in neural cells for Parkinson's disease treatment.

Outcome Details

RXR Nuclear Receptor Agonists promote clearance of alpha-synuclein in cellular models

Importance:4/10

Sentiment:

0.60

Parkinson's diseaseNeurodegenerative diseaseCellular modelsAlpha-synucleinPreclinical data

Related Companies

$DRTSW

Read the original article

Published by GlobeNewswire Clinical Studies on August 5, 2026 4:30 PM

Read Original